New England Biolabs Narrows Patent Infringement Lawsuit Against Enzymatics | GenomeWeb

NEW YORK (GenomeWeb News) –A lawsuit filed by New England Biolabs against Enzymatics has been "significantly narrowed," Enzymatics announced this week.

New England Biolabs has withdrawn its claims that Enzymatics infringed US Patent No. 5,670,637 and "conceded that US Patent No. 5,874,557 has expired, withdrawing its request for injunctive relief," Enzymatics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.